La vendita allo scoperto per Athira Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Athira Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Athira Pharma (NASDAQ:ATHA) Azioni, Report sulle vendite allo scoperto

Athira Pharma

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Athira Pharma Inc

Atha Energy Corp

Athabasca Minerals Inc

ATHABASCA OIL CORP by Athabasca Oil Corp.

Athabasca Oil Corp

WIIM

IONQ

IonQ shares are trading higher amid recent momentum in quantum-linked stocks.

Trading Ideas

LNKS

Linkers Industries Shares Halted To The Downside; Stock Now Down -21.69%

QBTS

D-Wave Quantum Inc. shares are trading higher amid continued momentum in quantum stocks.

WIMI

WiMi Hologram Cloud shares are trading higher after the company announced the development of a Quantum Technology-Based Random Access Memory Architecture.

KULR

KULR Technology shares are trading higher. The company announced it invested $21M in Bitcoin as part of its treasury strategy.

<p>Financial giants have made a conspicuous bullish move on IonQ. Our analysis of options history for IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) revealed 40 unusual trades.</p>
<p>Delving into the details, we found 42% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $225,930, and 35 were calls, valued at $4,686,955.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $65.0 for IonQ, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of IonQ stands at 1094.17, with a total volume reaching 38,651.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in IonQ, situated within the strike price corridor from $25.0 to $65.0, throughout the last 30 days.</p>
<h3>IonQ 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1735231543_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.5</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$65.00</td>
<td>$810.0K</td>
<td align="right">678</td>
<td>4.2K</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/03/25</td>
<td>$10.4</td>
<td>$10.2</td>
<td>$10.4</td>
<td>$35.00</td>
<td>$208.0K</td>
<td align="right">183</td>
<td>1.1K</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/03/25</td>
<td>$10.4</td>
<td>$10.15</td>
<td>$10.4</td>
<td>$35.00</td>
<td>$208.0K</td>
<td align="right">183</td>
<td>900</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/03/25</td>
<td>$10.4</td>
<td>$10.05</td>
<td>$10.38</td>
<td>$35.00</td>
<td>$207.8K</td>
<td align="right">183</td>
<td>700</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/03/25</td>
<td>$10.4</td>
<td>$10.05</td>
<td>$10.38</td>
<td>$35.00</td>
<td>$207.6K</td>
<td align="right">183</td>
<td>300</td>
</tr>
</tbody>
</table>
</p>
<h3>About IonQ</h3>
<p>IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems, and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.</p>
<p>Following our analysis of the options activities associated with IonQ, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of IonQ</h3>
<ul>
<li>Currently trading with a volume of 11,841,948, the IONQ's price is up by 4.31%, now at $46.5. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>What Analysts Are Saying About IonQ</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $47.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from DA Davidson has revised its rating downward to Buy, adjusting the price target to $50.<br />
&#x2A; An analyst from Craig-Hallum persists with their Buy rating on IonQ, maintaining a target price of $45. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for IonQ, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Market Whales and Their Recent Bets on IONQ Options

<p>Investors with significant funds have taken a bullish position in Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in DVN usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 14 options transactions for Devon Energy. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 42% being bullish and 42% bearish. Of all the options we discovered, 13 are puts, valued at $6,851,285, and there was a single call, worth $45,091.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $47.5 for Devon Energy over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Devon Energy's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Devon Energy's substantial trades, within a strike price spectrum from $25.0 to $47.5 over the preceding 30 days.</p>
<h3>Devon Energy Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1735231537_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.3</td>
<td>$10.35</td>
<td>$11.9</td>
<td>$42.50</td>
<td>$6.2M</td>
<td>2.4K</td>
<td>5.2K</td>
</tr>
<tr>
<td>DVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1.22</td>
<td>$1.09</td>
<td>$1.21</td>
<td>$25.00</td>
<td>$193.6K</td>
<td>75</td>
<td>1.6K</td>
</tr>
<tr>
<td>DVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.85</td>
<td>$8.75</td>
<td>$8.8</td>
<td>$40.00</td>
<td>$58.9K</td>
<td>4.3K</td>
<td>75</td>
</tr>
<tr>
<td>DVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$35.00</td>
<td>$56.6K</td>
<td>8.4K</td>
<td>988</td>
</tr>
<tr>
<td>DVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.5</td>
<td>$32.50</td>
<td>$51.3K</td>
<td>1.4K</td>
<td>1</td>
</tr>
</tbody>
</table>
</p>
<h3>About Devon Energy</h3>
<p>Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2023, Devon reported net proved reserves of 1.8 billion barrels of oil equivalent. Net production averaged roughly 658,000 barrels of oil equivalent per day in 2023 at a ratio of 73% oil and natural gas liquids and 27% natural gas.</p>
<h3>Where Is Devon Energy Standing Right Now?</h3>
<ul>
<li>With a volume of 2,702,144, the price of DVN is down -0.14% at $31.2. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 61 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Devon Energy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Devon Energy Unusual Options Activity For December 26

<p>Deep-pocketed investors have adopted a bullish approach towards Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 40% bearish. Among these notable options, 4 are puts, totaling $243,720, and 6 are calls, amounting to $226,072.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $50.0 for Viking Therapeutics over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Viking Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Viking Therapeutics's substantial trades, within a strike price spectrum from $30.0 to $50.0 over the preceding 30 days.</p>
<h3>Viking Therapeutics Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1735231532_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.5</td>
<td>$10.3</td>
<td>$10.4</td>
<td>$50.00</td>
<td>$126.8K</td>
<td>1.0K</td>
<td align="right">184</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.7</td>
<td>$7.3</td>
<td>$7.37</td>
<td>$50.00</td>
<td>$65.8K</td>
<td>2.0K</td>
<td align="right">97</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$44.50</td>
<td>$46.7K</td>
<td>3</td>
<td align="right">117</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.6</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$50.00</td>
<td>$41.6K</td>
<td>1.0K</td>
<td align="right">62</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.76</td>
<td>$50.00</td>
<td>$37.6K</td>
<td>3.8K</td>
<td align="right">402</td>
</tr>
</tbody>
</table>
</p>
<h3>About Viking Therapeutics</h3>
<p>Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.</p>
<p>Having examined the options trading patterns of Viking Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Viking Therapeutics</h3>
<ul>
<li>With a trading volume of 694,938, the price of VKTX is down by -0.83%, reaching $42.0.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Viking Therapeutics</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $95.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102.<br />
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $74.<br />
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102.<br />
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


VKTX

Unpacking the Latest Options Trading Trends in Viking Therapeutics

AMPG

Amplitech Group shares are trading higher. The stock initially traded lower after the company announced a $5.8 million registered direct offering, but it has since reversed.

MSTR

MicroStrategy shares are trading lower amid a pullback in Bitcoin.

<p>The automotive industry could be one of the American sectors hit hardest by President-elect<strong> Donald Trump's</strong> announced tariff plans on<a href="https://www.benzinga.com/news/global/24/12/42402629/trump-to-change-dollar-stores-for-good-dollar-tree-exec-says-prepared-to-act"> Canada and Mexico.</a></p>
<p><strong>What Happened: </strong>The incoming White House administration could significantly impact various industries and influence pricing for everyday goods and less frequently purchased items, <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42247850/gm-other-us-automakers-brace-for-sharp-profit-squeeze-from-trump-tariffs-analysts-warn">such as automobiles.</a></p>
<p>Several popular vehicles that sell for under $30,000 in the U.S. are currently built in Mexico. A proposed 25% tariff on automobiles imported into the U.S. from Mexico could take these vehicles over this pricing level quickly.</p>
<p>In fact, around one-third of all vehicles below $30,000 in the U.S. are currently built in Mexico, according to data from Edmunds, as <a href="https://www.wsj.com/business/autos/trump-tariff-plan-affordable-car-price-increase-1f3d4687?mod=hp_lead_pos2">reported </a>by the Wall Street Journal. This figure has risen from around one-fifth of all vehicles under the affordable auto price point around 10 years ago.</p>
<p>Popular models like the Ford Maverick from<strong> Ford Motor Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and Nissan Sentra from Nissan were named in the report.</p>
<p>Ford recently <a href="https://www.benzinga.com/24/12/42660866/trump-gets-ford-vehicles-1m-for-inauguration-will-musk-respond-or-could-he-ride-in-rival-vehicle">announced a $1 million </a>donation to Trump's inauguration and the donation of several fleet vehicles.</p>
<p>The Honda Civic from <strong>Honda Motor Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) is made at several manufacturing plants, including one in Canada. Import tariffs on Canada could impact the price of this top-selling sedan model.</p>
<p><strong>Kia </strong>is another automotive company that could be highly impacted by Trump's tariff plans. The company has several models, including the Forte and K4, which were made in Mexico before being imported into the United States.</p>
<p>The Forte and K4 sedans make up around 18% of Kia's U.S. sales according to the report.</p>
<p>"Everyone's got a pretty big case of anxiety here," Kia America Chief Operating Officer <strong>Steven Center </strong>said. "In two words: Please don't. Punch me in the arm. Smack me in the head. But please don't put a tariff on."</p>
<p><strong>General Motors Company </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), which also donated $1 million to Trump's inauguration, has several assembly factories in Mexico. The automotive company sources approximately one-third of its U.S. vehicle sales from plants in Mexico.</p>
<p><strong>Check This Out:</strong></p>
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent122624"><strong>Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</strong></a></li>
</ul>
<p><strong>Why It's Important:</strong> Trump's current plan is for 25% tariffs on items imported from Mexico, which could change a free-trade negotiation the president-elect worked on during his previous White House term.</p>
<p>Mexico has often been a place for manufacturing American automobiles that are known for their cheaper price points to help offset some of the costs of production. Around four million vehicles are made in Mexico annually according to the report, with close to 70% imported to the United States.</p>
<p>The signing of the North American Free Trade Agreement, also known as NAFTA, saw American companies turn to Mexico for cheaper labor rates for workers and ample land to build large manufacturing facilities.</p>
<p>Small sedans and SUVs, some of the most affordable options for consumers, are often manufactured in Mexico. The lower production costs help automotive companies turn a modest profit on these vehicles, which would likely result in losses if produced in the United States.</p>
<p>Tariffs on automobiles made in Mexico could change the sector, with auto companies deciding to move manufacturing to the United States or keep it in Mexico with the import tariffs. Either way, American consumers may face higher costs, whether from tariffs or increased expenses tied to U.S. manufacturing, potentially leading to the disappearance of many sub-$30,000 vehicle models.</p>
<p>A Wolfe Research estimate said $3,000 could be added to the cost of the average car sold in America, the report said.</p>
<p>This could be bad news for American consumers already facing higher costs on other items and comes after automotive prices soared during the COVID-19 pandemic due to supply shortages.</p>
<p>American consumers are paying an average of $700 monthly for loans on new automobiles, compared to an average of $500 back in 2016. Around 20% of American consumers are paying an average of $1,000 monthly for their auto loan payment, according to data from Edmunds.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/24/12/42536470/costco-warns-that-tariffs-raise-prices-trump-team-says-trade-policies-will-make-life-affordable">Costco Warns That Tariffs Raise Prices, Trump Team Says Trade Policies Will &#8216;Make Life Affordable&#8217;</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Government

Regulations

Politics

Global

Are Sub-$30,000 Cars Disappearing? Trump's Tariff Plans Could Reshape US Auto Market

RKLB

Rocket Lab shares are trading higher. The stock may be moving amid continued strength after the company on Monday announced that it completed its 16th successful mission of 2024.

VUZI

Vuzix Option Alert: 1,950 Jan 2026 $7 Calls Traded At The Ask For $1.90 With Open Interest Of 468; Stock Reference Price $5.00

XPEV

Shares of Chinese EV stocks are trading higher amid recent reports of a Chinese stimulus plan.

LASE

Laser Photonics shares are trading higher after the company announced it received an order from Walsh Service Solutions.

<p><strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is navigating a period of guarded optimism, according to a new report from <strong>Messari</strong>, buoyed by institutional inflows into newly approved ETFs and the promises made by the <a href="https://www.benzinga.com/24/12/42640293/trump-congratulates-bitcoiners-on-new-all-time-highs-as-apex-crypto-suffers-first-weekly-loss-since-election-triumph">new presidential administration</a>.</p>
<p><strong>What Happened: </strong>The <a href="https://messari.io/report-pdf/a929cd003f5eec790275e05ae8ef28cf4a6b4bfc.pdf">report</a> suggests that Bitcoin&#8217;s future trajectory depends on whether the administration can convert campaign rhetoric into tangible policy outcomes.</p>
<p>Bitcoin experienced a significant price surge in 2024, reaching a preliminary all-time high of $75,000 in the first quarter after the launch of Bitcoin ETFs and another all-time high of $108,000 in December.</p>
<p>Institutions were overwhelmingly net buyers of Bitcoin throughout the year, with <strong>Grayscale</strong>&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>) outflows decreasing substantially and <strong>Blackrock</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) emerging as the largest net buyer.</p>
<p>ETF issuers now hold over 1.1 million BTC, with <strong>Blackrock </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NASDAQ">BLK</a>) and Grayscale holding the majority.</p>
<p><strong>MicroStrategy </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has continued to actively invest in Bitcoin, with total holdings now exceeding 420,000 BTC after a recent purchase of $2.1 billion.</p>
<p>The company intends to raise a further $42 billion to fund additional purchases over the next three years. </p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42672990/solana-surged-2000-in-2-years-but-it-could-go-even-higher-report">Solana Surged 2,000% In 2 Years, But It Could Go Even Higher: Report</a></strong></p>
<p>The election of a new president who has expressed positive sentiments towards crypto has created a hopeful environment for the sector. </p>
<p>Some of his stated promises include firing SEC commissioner <strong>Gary Gensler</strong>, introducing a national strategic Bitcoin reserve, forming a Bitcoin and crypto presidential council, and ensuring Bitcoin mining in the U.S. </p>
<p>While a federal strategic Bitcoin reserve is unlikely, the report emphasizes that achieving some of the higher-probability policy items could sustain the current market enthusiasm.</p>
<p>The Bitcoin network is undergoing a significant evolution with the introduction of Ordinals and Runes, which have enabled NFTs and fungible tokens, bringing new functionality. </p>
<p>Bitcoin&#8217;s staking protocol <strong>Babylon </strong>is also a new development, allowing holders to stake their assets to secure other networks. </p>
<p>Despite these developments, the report notes the network was not designed for maximum programmability, but a low penetration of Bitcoin utility could exceed $30 billion in market value.</p>
<p>Messari projects that institutional ETF inflows will continue to be a primary driver of price action, which could lead to more stable, less volatile price movements. </p>
<p>The report also acknowledges that the success of new developments like Runes, Ordinals, and Bitcoin staking will depend on user adoption and the continued improvement of the user experience.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42669525/bitcoins-rally-tracked-this-crucial-macro-indicatorand-now-its-pointing-to-a-correction">Bitcoin&#8217;s Rally Tracked This Crucial Macro Indicator—And Now It&#8217;s Pointing To A Correction</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

GBTC

IBIT

Bitcoin Investors Should Be Optimistic Ahead Of 2025: Here's Why

<p>Deep-pocketed investors have adopted a bullish approach towards JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for JD.com. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 3 are puts, totaling $176,692, and 7 are calls, amounting to $369,159.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $60.0 for JD.com over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for JD.com options trades today is 13666.78 with a total volume of 5,844.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for JD.com's big money trades within a strike price range of $30.0 to $60.0 over the last 30 days.</p>
<h3>JD.com Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1735229735_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.26</td>
<td>$1.95</td>
<td>$2.25</td>
<td>$60.00</td>
<td>$111.2K</td>
<td>4.2K</td>
<td>0</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.86</td>
<td>$0.81</td>
<td>$0.81</td>
<td>$35.00</td>
<td>$95.2K</td>
<td>19.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.6</td>
<td>$4.55</td>
<td>$4.6</td>
<td>$33.00</td>
<td>$91.5K</td>
<td>319</td>
<td>200</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.88</td>
<td>$0.83</td>
<td>$0.83</td>
<td>$35.00</td>
<td>$49.8K</td>
<td>19.5K</td>
<td>600</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.6</td>
<td>$0.54</td>
<td>$0.54</td>
<td>$40.00</td>
<td>$49.6K</td>
<td>61.9K</td>
<td>1.9K</td>
</tr>
</tbody>
</table>
</p>
<h3>About JD.com</h3>
<p>JD.com is a leading e-commerce platform with its 2022 China GMV being similar to Pinduoduo (GMV not reported), on our estimate, but still lower than Alibaba. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.</p>
<p>After a thorough review of the options trading surrounding JD.com, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of JD.com</h3>
<ul>
<li>Trading volume stands at 1,841,224, with JD's price down by -0.71%, positioned at $36.2.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>What The Experts Say On JD.com</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $46.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Bernstein has elevated its stance to Outperform, setting a new price target at $46. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for JD.com, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


JD.com Options Trading: A Deep Dive into Market Sentiment

<p>Financial giants have made a conspicuous bullish move on Nike. Our analysis of options history for Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 58% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $147,507, and 9 were calls, valued at $319,833.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $76.0 to $100.0 for Nike during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Nike stands at 4755.38, with a total volume reaching 2,026.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Nike, situated within the strike price corridor from $76.0 to $100.0, throughout the last 30 days.</p>
<h3>Nike 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1735229729_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$3.0</td>
<td>$2.89</td>
<td>$2.89</td>
<td>$76.00</td>
<td>$57.8K</td>
<td>101</td>
<td align="right">400</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.75</td>
<td>$5.6</td>
<td>$5.72</td>
<td>$80.00</td>
<td>$49.7K</td>
<td>4.6K</td>
<td align="right">87</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.45</td>
<td>$7.3</td>
<td>$7.3</td>
<td>$82.50</td>
<td>$48.9K</td>
<td>1.4K</td>
<td align="right">134</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$80.00</td>
<td>$48.8K</td>
<td>4.6K</td>
<td align="right">174</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$16.1</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$77.50</td>
<td>$45.0K</td>
<td>4.8K</td>
<td align="right">30</td>
</tr>
</tbody>
</table>
</p>
<h3>About Nike</h3>
<p>Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.</p>
<p>In light of the recent options history for Nike, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Nike's Current Market Status</h3>
<ul>
<li>With a volume of 1,680,559, the price of NKE is up 0.27% at $77.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
<h3>What The Experts Say On Nike</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $80.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Nike with a target price of $73.<br />
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Nike with a target price of $97.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Nike with a target price of $70.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Nike, which currently sits at a price target of $80.<br />
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $84. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Nike, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Smart Money Is Betting Big In NKE Options

RYDE

Ryde Group shares are trading higher after the company announced it renewed its 3-year ride-hail and carpool licenses in Singapore.

<p>Financial giants have made a conspicuous bearish move on Hims &amp; Hers Health. Our analysis of options history for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 11% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $139,520, and 5 were calls, valued at $233,968.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $15.0 and $37.0 for Hims &amp; Hers Health, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Hims &amp; Hers Health's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Hims &amp; Hers Health's whale trades within a strike price range from $15.0 to $37.0 in the last 30 days. </p>
<h3>Hims &amp; Hers Health Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1735229724_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.0</td>
<td>$2.85</td>
<td>$2.9</td>
<td>$28.00</td>
<td>$72.7K</td>
<td>3.2K</td>
<td>12</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$5.8</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$27.00</td>
<td>$56.0K</td>
<td>793</td>
<td>210</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.25</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$35.00</td>
<td>$44.0K</td>
<td>3.8K</td>
<td>294</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.14</td>
<td>$30.00</td>
<td>$40.9K</td>
<td>478</td>
<td>1.5K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.16</td>
<td>$30.00</td>
<td>$39.9K</td>
<td>478</td>
<td>1.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hims &amp; Hers Health</h3>
<p>Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.</p>
<p>In light of the recent options history for Hims &amp; Hers Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Hims &amp; Hers Health Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,915,986, the price of HIMS is down by -0.18%, reaching $28.1.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 60 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Hims &amp; Hers Health</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $40.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Morgan Stanley downgraded its rating to Overweight, setting a price target of $42.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Hims &amp; Hers Health, targeting a price of $38. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Hims &amp; Hers Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Hims & Hers Health, Inc. Class A Common Stock

HIMS

Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

06:26 EDT Athira Pharma (ATHA) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving brea...

Athira Pharma files $300M mixed securities shelf

Athira Pharma (ATHA) announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer's disease will be presente...

Athira Pharma to present results from Phase 2/3 LIFT-AD trial

Vast Renewables, Theriva Biologics, and Athira Pharma are the 3 Penny Stocks to watch on November 5, 2024, based on&nbsp;TipRanks' Penny Stock Scre...

3 Penny Stocks to Watch Now, 11/5/24

"We are pleased to be continuing the advancement of ATH-1105 as a potential treatment for ALS. This novel, oral, next-generation HGF-modulating dru...

Athira Pharma reports Q3 EPS (75c), consensus (71c)

Athira Pharma GAAP EPS of -$0.75 misses by $0.04

JMP Securities analyst Jason Butler reiterated a Hold rating on Athira Pharma (ATHA – Research Report) today. The company's shares closed yesterday...

JMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)

Athira Pharma, Inc. ( ($ATHA) ) has released its Q3 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors...

Athira Pharma Reports Q3 2024 Financial Results

Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category. Athira Pharma, Inc. faces significant business risk due to its dep...

Athira Pharma's Regulatory Compliance Challenges Threaten Drug Development Pipeline

Athena Gold upsizes private placement from C$1M to up to C$1.25M

ABUS

AHNR

ALPMF

ALPMY

ANTX

ATHA

BAYRY

BAYZF

BBIO

BMRN

CDTX

CRBU

CVAC

FGEN

GLYC

HLVX

IBRX

INAB

LXRX

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

TOVX

VIRX

VSTE

Biotech

Press Releases

General

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

Health Care

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Earnings

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Comments

Athira Pharma

Vendite allo scoperto

Athira Pharma (NASDAQ:ATHA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO